Nimish P Shah
CIK 1698082 · last filed 2026-09-10
Nimish P Shah is a corporate insider who has filed 14 SEC Form 4 insider transactions across 6 companies since 2019. The most recent filing, for KRSA, was dated Sep 10, 2026. Across all open-market trades the lifetime net is −$2.2M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $133.0K across reported positions. 57 SEC filings were submitted jointly with VHCP Co-Investment Holdings III, LLC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
KALV price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
23RD FLOOR
NEW YORK CITY, NY 10018
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KRSA | Director | — | — | — | $0 | 1 | 2026-09-10 |
| Apogee Therapeutics, Inc. (APGE) Delisted | Director | 0 | $135.07 | $0 | $29.75M | 6 | 2026-09-03 |
| Tricida, Inc. (TCDA) Delisted | 10%+ Owner | 9,570,800 | $0.11 | $1.03M | $77.58M | 3 | 2022-10-11 |
| VTGN | 10%+ Owner | 687,910 | $0.17 | $119.6K | -$534.0K | 1 | 2022-07-14 |
| TIL | Director | 2,420 | $5.57 | $13.5K | $6.00M | 2 | 2021-03-25 |
| KalVista Pharmaceuticals, Inc. (KALV) Delisted | 10%+ Owner | 1,544,112 | $27.00 | $41.69M | -$115.00M | 1 | 2019-03-20 |
Recent Filings
14 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-09-10 | KRSA | Grant (A) | — | $0 | EDGAR |
| 2026-09-03 | Apogee Therapeutics, Inc. (APGE) Delisted | Disp (D) | −1,750,000 | -$236.44M | EDGAR |
| 2026-06-11 | Apogee Therapeutics, Inc. (APGE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-10-15 | Apogee Therapeutics, Inc. (APGE) Delisted | Buy (P) | — | $0 | EDGAR |
| 2025-06-20 | Apogee Therapeutics, Inc. (APGE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-06-07 | Apogee Therapeutics, Inc. (APGE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-07-17 | Apogee Therapeutics, Inc. (APGE) Delisted | Mixed | +1,750,000 | $29.75M | EDGAR |
| 2022-10-11 | Tricida, Inc. (TCDA) Delisted | Buy (P) | +1,342,140 | $15.98M | EDGAR |
| 2022-09-28 | Tricida, Inc. (TCDA) Delisted | Buy (P) | +5,872,140 | $52.25M | EDGAR |
| 2022-07-14 | VTGN | Sell (S) | −600,000 | -$534.0K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.